-
公开(公告)号：US09340520B2
公开(公告)日：2016-05-17
申请号：US14017837
申请日：2013-09-04
Applicant: Bristol-Myers Squibb Company
Inventor： Omar D. Lopez , John A. Bender , Makonen Belema
IPC: C07D309/06 , C07D405/14 , A61K45/06 , A61K31/4178
CPC classification number: C07D309/06 , A61K31/4178 , A61K45/06 , C07D405/14 , A61K2300/00
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US09326973B2
公开(公告)日：2016-05-03
申请号：US13735224
申请日：2013-01-07
Applicant: Bristol-Myers Squibb Company
Inventor： Piyasena Hewawasam , John F. Kadow , Omar D. Lopez , Nicholas A. Meanwell , Yong Tu , Alan Xiangdong Wang , Ningning Xu , Samayamunthula Venkata Satya Arun Kumar Gupta , Pothukanuri Srinivasu , Indasi Gopi Kumar , Ponugupati Suresh Kumar , Makonen Belema , Robert A. Fridell , Min Gao , Julie A. Lemm , Donald R. O'Boyle, II , Jin-Hua Sun , Chunfu Wang , Ying-Kai Wang
IPC: A61K31/415 , A61K31/675 , A61K38/00 , A61K31/4178 , A61K31/407 , A61K31/4184 , A61K31/422 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/7056 , A61K38/05 , A61K38/21 , A61K45/06 , C07D403/14 , C07D491/113
CPC classification number: A61K31/4178 , A61K31/407 , A61K31/4184 , A61K31/422 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/7056 , A61K38/05 , A61K38/21 , A61K38/212 , A61K38/217 , A61K45/06 , C07D403/14 , C07D491/113 , A61K2300/00
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
Abstract translation: 本公开通常涉及抗病毒化合物，更具体地涉及可以抑制丙型肝炎病毒（HCV）编码的NS5A蛋白的功能的化合物的组合，包含这些组合的组合物，以及用于抑制NS5A的功能的方法 蛋白。
-
公开(公告)号：US20150197499A1
公开(公告)日：2015-07-16
申请号：US14668090
申请日：2015-03-25
Applicant: Bristol-Myers Squibb Company
Inventor： Rico Lavoie , John A. Bender , Zhong Yang , Makonen Belema , Omar D. Lopez , Qi Chen , Gan Wang , Piyasena Hewawasam
IPC: C07D309/06
CPC classification number: C07D309/06 , A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US08846023B2
公开(公告)日：2014-09-30
申请号：US14021686
申请日：2013-09-09
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Gan Wang , Lawrence G. Hamann
IPC: C07D403/14 , C07D405/14 , C07D417/14 , A61K31/506 , A61K31/4178 , A61K31/427 , A61K31/13 , A61K31/7105 , A61K31/4745 , A61K31/7056 , A61K38/20 , A61K38/21 , C07D401/14
CPC classification number: A61K31/506 , A61K31/13 , A61K31/4178 , A61K31/427 , A61K31/4745 , A61K31/7056 , A61K31/7105 , A61K38/2013 , A61K38/204 , A61K38/208 , A61K38/21 , A61K38/212 , C07D401/14 , C07D403/14 , C07D405/14 , C07D417/14
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US20160311778A1
公开(公告)日：2016-10-27
申请号：US15194980
申请日：2016-06-28
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Gan Wang , Lawrence G. Hamann
IPC: C07D233/64 , C07D405/14 , C07D413/14 , C07D409/14 , C07D417/14 , C07D403/14 , C07D401/14
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
Patent Agency Ranking
公开(公告)号：US20160158200A1
公开(公告)日：2016-06-09
申请号：US14903024
申请日：2013-07-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Piyasena Hewawasam , Omar D. Lopez , Yong Tu , Alan Xiangdong Wang , Ningning Xu , John F. Kadow , Nicholas A. Meanwell , Samayamunthula Venkata Satya Arun Kumar Gupta , Indasi J. Gopi Kumar , Suresh Kumar Punugupati , Makonen Belema
IPC: A61K31/4178 , A61K31/444 , A61K31/4439 , A61K31/497 , A61K31/695 , A61K31/4545 , A61K31/5377 , A61K31/437 , A61K31/5365 , A61K31/519 , A61K45/06 , A61K31/4725
CPC classification number: A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/439 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/519 , A61K31/5365 , A61K31/5377 , A61K31/695 , A61K31/7056 , A61K38/21 , A61K45/06 , A61K2300/00
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
Abstract translation: 本公开通常涉及抗病毒化合物，更具体地涉及可以抑制丙型肝炎病毒（HCV）编码的NS5A蛋白的功能的化合物的组合，包含这些组合的组合物，以及用于抑制NS5A的功能的方法 蛋白。
-
公开(公告)号：US20150322048A1
公开(公告)日：2015-11-12
申请号：US14807084
申请日：2015-07-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Rico Lavoie , John A. Bender , Zhong Yang , Makonen Belema , Omar D. Lopez , Qi Chen , Gan Wang , Piyasena Hewawasam
IPC: C07D403/14 , A61K45/06 , A61K31/4178 , A61K31/4545 , C07D471/04 , A61K31/437 , C07D487/04 , A61K31/4985 , C07D405/14 , C07D401/14 , A61K31/4709 , A61K31/498 , A61K31/4375 , C07D413/14 , A61K31/5377 , A61K31/4184
CPC classification number: C07D309/06 , A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US20150297568A1
公开(公告)日：2015-10-22
申请号：US14753564
申请日：2015-06-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Piyasena Hewawasam , Omar D. Lopez , Yong Tu , Alan Xiangdong Wang , Ningning Xu , John F. Kadow , Nicholas A. Meanwell , Samayamunthula Venkata Satya Arun Kumar Gupta , Indasi J. Gopi Kumar , Suresh Kumar Ponugupati , Makonen Belema
IPC: A61K31/4178 , A61K38/21 , A61K31/7056 , A61K31/4184 , A61K31/4188 , A61K31/5377 , A61K31/519 , A61K31/695 , A61K31/4725 , A61K31/437 , A61K31/454 , A61K31/4545 , A61K31/402 , A61K31/5365
CPC classification number: A61K31/4178 , A61K31/402 , A61K31/4184 , A61K31/4188 , A61K31/4245 , A61K31/437 , A61K31/439 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/519 , A61K31/5365 , A61K31/5377 , A61K31/695 , A61K31/7056 , A61K38/2013 , A61K38/204 , A61K38/208 , A61K38/21 , A61K45/06 , C07D233/64 , C07D403/14 , C07D405/14 , C07D493/08 , A61K2300/00
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
Abstract translation: 本公开通常涉及抗病毒化合物，更具体地涉及可以抑制丙型肝炎病毒（HCV）编码的NS5A蛋白的功能的化合物的组合，包含这些组合的组合物，以及用于抑制NS5A的功能的方法 蛋白。
-
公开(公告)号：US09018390B2
公开(公告)日：2015-04-28
申请号：US13919027
申请日：2013-06-17
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Lawrence G. Hamann
IPC: C07D233/00 , C07D233/02 , A01N43/50 , A61K31/415 , C07D403/14 , A61K31/4178 , A61K31/4545 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07F7/10
CPC classification number: C07D403/14 , A61K31/4178 , A61K31/4545 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07F7/10
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Abstract translation: 本公开涉及用于治疗丙型肝炎病毒（HCV）感染的化合物，组合物和方法。 还公开了含有这些化合物的药物组合物和使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US20150023913A1
公开(公告)日：2015-01-22
申请号：US13933495
申请日：2013-07-02
Applicant: Bristol-Myers Squibb Company
Inventor： Piyasena Hewawasam , Omar D. Lopez , Yong Tu , Alan Xiangdong Wang , Ningning Xu , John F. Kadow , Nicholas A. Meanwell , Samayamuthula Venkata Satya Arun Kumar Gupta , Indasi J. Gopi Kumar , Suresh Kumar Ponugupati , Makonen Belema
IPC: A61K38/21 , A61K31/4178 , A61K31/7056 , A61K31/4245 , C07D233/64 , C07D403/14 , C07D493/08 , A61K31/4725 , C07D405/14 , A61K45/06
CPC classification number: A61K31/4178 , A61K31/402 , A61K31/4184 , A61K31/4188 , A61K31/4245 , A61K31/437 , A61K31/439 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/519 , A61K31/5365 , A61K31/5377 , A61K31/695 , A61K31/7056 , A61K38/2013 , A61K38/204 , A61K38/208 , A61K38/21 , A61K45/06 , C07D233/64 , C07D403/14 , C07D405/14 , C07D493/08 , A61K2300/00
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.092 seconds)
